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patient-rated quality of life
subjective well-being
neurocognitionLack of insight is a well-established phenomenon in schizophrenia, and has been associated with reduced rater-
assessed functional performance but increased self-reported well-being in previous studies. The objective of this
study was to examine factors that might inﬂuence insight (as assessed by the Insight and Treatment Attitudes Ques-
tionnaire [ITAQ] or PANSS item G12) and subjective quality-of-life (as assessed by Lehman QoL Interview [LQOLI]),
using the large National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)
dataset. Uncooperativeness was assessed by PANSS item G8 (“Uncooperativeness”). In the analysis, we found signif-
icantmoderating effects for insight on the relationships of subjective life satisfaction assessment to symptom severity
(as assessed by CGI-S score), objective everyday functioning (as assessed by rater-administered Heinrichs–Carpenter
Quality of Life scale), clinically rated uncooperativeness (as assessed by PANSS G8), and discontinuation of treatment
for all causes (all Pb 0.05 for statistical interactionbetween insight and subjectQoL). Patientswith chronic schizophre-
niawho reported being "pleased" or "delighted" on LQOLIwere found to have signiﬁcantly lower neurocognitive rea-
soning performance and poorer insight (ITAQ total score). Our ﬁndings underscore the importance of reducing
cognitive and insight impairments for both treatment compliance and improved functional outcomes.© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Clinicians, researchers and healthcare authorities have come to rec-
ognize personal recovery and reintegration into society as attainable
goals in the treatment of chronic, serious mental illness (Farkas, 2007;
Frese et al., 2009). Accordingly, the mental health community has
shifted its focus from primarily symptom amelioration to the pursuit
of improving functioning and quality of life (QoL) outcomes. It is gener-
ally understood that QoL is a multidimensional construct, including
both objective measures such as rater-assessed independent living,
vocational, family and community functioning, and subjectivemeasures
such as patient self-reported well-being and life satisfaction (subjective
QoL) (Narvacz et al., 2008; Test et al., 2005).
In people with schizophrenia, existing ﬁndings suggest that symp-
toms have only a modest relationship to QoL (Eack and Newhill,
2007), whereas neurocognitive deﬁcits, highly prevalent in schizophre-
nia, are key factors for poor everyday outcomes (Elvevag and Goldberg,
2000; Green, 1996; Green et al., 2000; Harvey and Keefe, 2001; Harveyenis Street, #239, Montreal, QC
. This is an open access article underet al., 2004, 2013). While the relationship between neurocognitive per-
formance and objective measures of functional capacity has been well
established (Bowie et al., 2006, 2010; Harvey et al., 2009, 2011, 2013),
studies investigating the linkage between cognitive performance, objec-
tive QoL, and subjective, patient-rated well-being have reported con-
ﬂicting results (Brekke et al., 2001; Tolman and Kurtz, 2012). Some
studies reported positive correlations between neurocognitive perfor-
mance and objective QoL (as assessed by Heinrichs–Carpenter Quality
of Life Scale) (Addington and Addington, 2008; Heinrichs et al., 1984;
Lysaker and Davis, 2004; Savilla et al., 2008) or subjective well-being
(QoL) (Alpetkin et al., 2005; Herman, 2004). Others, however, reported
an inverse relationship between neurocognitive performance and sub-
jective QoL (Corrigan and Buican, 1995; Kurtz and Tolman, 2011;
Narvacz et al., 2008), or even no relationships between neurocognitive
deﬁcits and either objective or subjective quality of life (Agid et al.,
2012; Chino et al., 2009; Fiszdon et al., 2008; Smith et al., 1999).
Lack of insight into illness is a well-established phenomenon in
schizophrenia, with the estimated prevalence of poor insight ranging
from 50% (Amador et al., 1993) to 81% (Wilson et al., 1986) of individ-
uals with schizophrenia. Although little is known about the underlying
mechanism(s), poor insight has been linked to cognitive impairment,
increased re-hospitalization rates, worse clinical outcome (Kurtz andthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Baseline patient self-report well-being and insight towards illness in
chronic schizophrenia.
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function (Francis and Penn, 2001; Frank and Gunderson, 1990; Lysaker
et al., 1998), and barriers to engagement in treatment (Arango and
Amador, 2011; Cuffel et al., 1996; Olfson et al., 2006).
Reduced insight into illness and poorer acceptance of treatment in
schizophrenia have been found to be associated with lower depressive
symptoms and higher subjective QoL in previous research (Kurtz and
Tolman, 2011; Lysaker et al., 2009; Mintz et al., 2003; Morgan and
David, 2006; Narvacz et al., 2008; Sellwood et al., 2013; Tolman and
Kurtz, 2012), including the Clinical Antipsychotic Trial of Intervention
Effectiveness (CATIE) schizophrenia study (Mohamed et al., 2009).
This inverse relationship between subjective QoL and insight into illness
(Eack and Newhill, 2007; Tolman and Kurtz, 2012) challenges our con-
ventional model on treatment strategies for mental illness, which
assumes treatment of symptoms will lead to improved insight, func-
tional outcomes and subjective QoL (i.e. well-being) (Carling, 1995).
However, our recent paper (Gould et al., 2015) showed that inability
to accurately estimate cognitive and everyday functional skills was a
stronger predictor of impairments in everyday functioning than clinical
symptoms, cognitive functioning and the ability to perform everyday
functional skills. We hereby hypothesized that insight impairment
would moderate relationships of patient-rated well-being (subjective
QoL) to symptoms, objective functioning, and discontinuation of treat-
ment. Inter-relationships between insight, neurocognitive functioning,
and subjective QoL were also evaluated in analyzing data from the Clin-
ical Antipsychotic Trial of Intervention Effectiveness (CATIE) in schizo-
phrenia study (Lieberman et al., 2005).
2. Methods
This post-hoc analysis used data from the CATIE study in patients
with chronic schizophrenia (Lieberman et al., 2005). Insight and atti-
tudes towards medications were assessed by the Insight and Treatment
Attitudes Questionnaire (ITAQ) (McEvoy et al., 1989) and PANSS item
G12 ("lack of judgment and insight") (Kay et al., 1987), respectively.
The ITAQ is a semi-structured interview scale consisting of 11 items
that measure awareness of illness (5 items) and attitude towards treat-
ment (6 items). Total score ranges from0 (no insight) to 22 ("full insight",
no impairment). Insight impairment was deﬁned categorically as PANSS
G12 ≥ 4 (moderate to extreme) and ITAQ total score not indicating "full
insight" (=22). Objective functioning was assessed using the rater-
administered Heinrichs–Carpenter Quality of Life (HQOL) scale
(Heinrichs et al., 1984). The HQOL scale is a 21-item clinician-rated
scale rated from 0 (severe impairment) to 6 (normal/unimpaired),
assessing 4 domains, namely, interpersonal relations, instrumental role,
intrapsychic foundations, and participation in community (common ob-
jects and activities). The HQOL total score ranges from 0 to 6. Subjective
QoL was assessed by the single item from the Lehman QOL Interview
(LQOLI) that asks patients to rate their level of well-being on a 7-point
scale: from terrible = 1, unhappy = 2, mostly dissatisﬁed = 3,
mixed = 4, mostly satisﬁed = 5, pleased = 6, to delighted = 7
(Lehman, 1988; Lehman and Burns, 1990). Neurocognitive functioning
was assessed by a battery of neurocognitive tests, reﬂecting 5 domains:
Processing Speed, Verbal Memory, Vigilance, Reasoning, and Working
Memory (Keefe et al., 2007). Clinical symptoms were assessed by the
Clinical Global Impression of Severity (CGI-S), a single-item clinician as-
sessment of overall illness severity on a 7-point scale, with higher
scores associated with greater illness severity (Guy, 1976). Depres-
sion was assessed by the Calgary Depression Scale for Schizophrenia
(CDSS) (Addington and Addington, 2008; Addington et al., 1990),
and uncooperativeness by PANSS item G8 (Kay et al., 1987).
Multiple regression method was applied to evaluate the inter-
relationships between the subjective QoL (sQoL as assessed by LQOLI),
objective functioning (as assessed by HQOL), cognition, dropouts, anduncooperativeness; aswell as themoderating effect that insight impair-
ment had on the inter-relationships of these clinical outcomes. The
moderating effects of insight were evaluated by the statistical interac-
tion term (insight-by-sQoL) in these models. The multivariate regres-
sion models were also adjusted for age and symptom severity (CGI-S)
to reduce the confounding effects of these variables.3. Results
3.1. Cross-sectional associations between symptoms, insight into illness,
neurocognitive function, and patients' self-rated satisfaction with life
Fig. 1 shows that lack of insight and medication acceptance were in-
versely related to patients' self-rated, subjective satisfaction with life
(LQOLI) in chronic schizophrenia (P= 0.03; P= 0.004 after accounting
for age and symptom severity as assessed by CGI-S). Age (related to ill-
ness duration) and CGI-S were included as confounding variables in the
regression models, because of their signiﬁcant correlations with insight
in univariate analysis (all P b 0.007). When compared to those rated
"mostly dissatisﬁed" or below (≤3) on a scale from 1 (=terrible) to 7
(=delighted), patients who rated "delighted' (7) or "pleased" (6) on
LQOLI had signiﬁcantly higher levels of impairment in the
neurocognitive composite score (P = 0.011, mean composite score
−0.11 vs. +0.10 [SD= 1]), and neurocognitive domains that included:
reasoning and problem solving (P = 0.001, mean −0.16 vs. +0.11,
SD = 0.996), and vigilance (P = 0.012, mean−0.08 vs. +0.14, SD =
0.997). The inverse relationship between higher subjective life satisfac-
tion score and the lack of insight into illness could be explained, in part,
by the high level of impairment in reasoning and problem solving
(P b 0.05), aswell as the low level of self-reported depressive symptoms
(P b 0.001) after adjusting for age and symptom severity (CGI-S) in a
multivariate regression model (Fig. 2, Table 1). These two factors, low
levels of depression and impaired reasoning and problem solving, to-
gether accounted for about 77% of the aged-adjusted inverse relation-
ship between assessed insight into illness and self-reported well-being
(LQOLI). The inverse relationship between low insight into illness and
high subjective satisfaction of life was non-signiﬁcant (P = 0.487)
after depressive symptoms were entered into the model as a predictor.
Depressive symptoms (P b 0.001), neurocognitive reasoning (P =
0.036), and symptom severity (P= 0.031) remained signiﬁcant predic-
tors of subjective satisfactionwith life indicatingdirect effects,while age
and insight into illness were non-signiﬁcant (Table 1).
Fig. 2. Baseline patient self-report well-being, neurocognitive reasoning, and depression in chronic schizophrenia.
129C.O. Siu et al. / Schizophrenia Research: Cognition 2 (2015) 127–1323.2. Moderators of the relationship between insight into illness and patients'
self-rated satisfaction with life
Therewas a signiﬁcant correlation between the Insight and Treatment
Attitudes Questionnaire (ITAQ) total score and PANSS item G12 ("lack of
judgment and insight") (Spearman correlation r =−0.49, P b 0.001). In
the statistical interaction analysis to assess moderating effects, moderate
to extreme impairment in insight and judgment was deﬁned as PANSS
G12 ≥ 4 (moderate to extreme) and ITAQ total score b 22 where 22 rep-
resents full insight (no impairment). Among the 402 (33% of 1237) sub-
jects who had moderate to extreme PANSS G12 scores, 85 had ITAQ
score of 22 (full insight) and hence were excluded from the insight im-
pairment class in the analysis. Mild to absence of insight impairment
was deﬁned as PANSS G12 b 4 (mild to absent) or ITAQ total score =
22 (full insight, no impairment). Figs. 3–5 show the signiﬁcant moderat-
ing effects that insight into illness had on the relationships of subjective
life satisfaction assessment (LQOLI) to symptom severity (as assessed by
CGI-S score), everyday functioning (as assessed by rater-administered
HQOL scale), clinically rated uncooperativeness (as assessed by PANSS
G8), aswell as discontinuationof treatment for all causes. Greater satisfac-
tion with life was associated with lower symptom severity, better
HQOL functioning score, lower treatment dropout, and lower
uncooperativeness symptoms in patients with mild or absence of insight
impairment, while the relationship of subjective life satisfaction score to
symptom severity was reversed (i.e., greater satisfaction with life was as-
sociated with higher symptom severity) in patients withmoderate to ex-
treme impairment in insight and high satisfactionwith life (P=0.022 for
interaction effects of insight and subjective satisfaction of life scores on
CGI-S). Similar inverse trends were observed for the HQOL functioning
score and dropouts (all P b 0.05) (Figs. 4 and 5). The PANSSTable 1
Multivariate model for subjective patient's rated satisfaction of life.
Variables Estimate Standard Error t Value Pr N |t|
Intercept 5.48 0.256 21.42 b .001
Insight into illness −0.006 0.007 −0.84 0.399
Depression score −0.124 0.008 −14.93 b .001
Neurocognitive reasoning −0.080 0.038 −2.10 0.036
CGI-S −0.085 0.039 −2.16 0.031
age −0.004 0.003 −1.07 0.285uncooperativeness symptom was signiﬁcantly higher in patients with
lack of insight into illness and high subjective satisfaction with life, com-
pared to patients withmild insight impairment and high subjective satis-
faction with life (Fig. 5 right). We found consistent statistical interaction
test results using continuous ITAQ total score (ITAQ-by-sQoL interaction
effect) for all clinical outcomes in the moderator analysis. In particular,
statistical tests for ITAQ total score by sQoL interaction effect were signif-
icant for CGI-S (P= 0.0128), uncooperativeness (P= 0.0265), and objec-
tive functioning HQOL score (P = 0.002).
Greater satisfaction with life was associated with a lower all-cause
dropout rate but only in patients with greater insight and medication
acceptance. This trend of decreasing dropout rate with increased satis-
faction with life was reversed in the low insight group which exhibited
high, self-rated satisfactionwith life ("pleased" or "delighted" on LQOLI)
(P = 0.039, chi-square = 4.36, Cox model, adjusted for treatment, age,
marital status). Patients who had a high, self-rated satisfaction with life
("pleased" or "delighted") tended to be more severely ill (i.e., had a
higher CGI-S score) and were more likely to drop out of treatment in
the lower insight group, compared to the higher insight group.
4. Discussion
Our ﬁndings suggest that the relationships of subjective QoL to clin-
ical symptoms and treatment discontinuation depend on the level of in-
sight impairment into illness and attitude toward medications. These
results extend previous ﬁndings in the analysis of CATIE data by demon-
strating themoderating relationship of insight impairmentwith subjec-
tive QoL and objective functioning HQOL outcomes. Patients with
chronic schizophrenia who reported being "pleased" or "delighted" on
LQOLIwere liable to have lower neurocognitive reasoning performance,
plus lower insight into their illness and poorer attitude towards treat-
ment. These patients were more likely to discontinue treatment if
they exhibited moderate to extreme symptoms but rated their overall
well-being as "pleased" or "delighted".
The association between symptom severity and subjective QoL was
moderated by the subject's insight and judgment, such that at every re-
spective level of self-reported subjective QoL subjects with poor insight
suffered signiﬁcantly higher symptoms than their counterparts with bet-
ter insight (P = 0.022 for insight-by-subjective well-being interaction).
This was especially pronounced for the subgroup with the most insight
Fig. 3. Relationship between symptom severity and subjective life satisfaction assessment depended on level of insight impairment.
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"delighted" on LQOLI). The same pattern prevailed when it came to the
primary outcome of CATIE, all cause discontinuation of treatment during
the 18-month trial. Subjects with higher or lower levels of insight gener-
ally did not behave signiﬁcantly differently, except for the subgroup with
the most impaired insight which also reported high life satisfaction.
Patients in the CATIE trial who hadmoderate to severe insight impair-
ment were also signiﬁcantlymore likely to be uncooperative (as assessed
by PANSS itemG8 "uncooperativeness"), versus thosewith no ormild in-
sight impairment, irrespective of self-reported subjective QoL. These re-
sults suggest that those subjects with poor insight in addition to a
distorted sense of personal well-being were most likely to be uncoopera-
tive, and, hence, more likely to be non-compliant with treatment.
Further, our ﬁndings show that neurocognitive reasoning was signiﬁ-
cantly correlated with self-reported level of subjective well-being.
Subjects who scored high on the depression scale at baseline were signif-
icantly more likely (P b 0.001) to report lower satisfaction with life, asFig. 4. Relationship between Heinrichs–Carpenter Quality of Life and sureﬂected by low LQOLI scores. These results corroborate the large existing
literature suggesting that severity of depression is associated with poor
self-reported well-being (subjective QoL), and is responsible for the
poor prognosis and long-term outcome that subsequently follow
(Amador et al., 1994; Bowie et al., 2007; Ruggeri et al., 2005). Ourﬁndings
are consistent with recent research suggesting that patients with particu-
larly lowdepression scores are likely to over-estimate their cognitive abil-
ities and their level of everyday functioning (Durand et al., 2015).
In our analysis, we also identiﬁed a challenging subgroup of patients
with chronic schizophrenia who manifest marked psychiatric symp-
toms and poor insight. These individuals are prone to be more uncoop-
erative in treatment and hence predisposed to discontinue their
medications early, possibly related to potential "positive bias" in this
group of non-depressed patients, who rated "pleased or delighted" on
a subjective patients-rated well-being (LQOLI) but had higher CGI-S
score and lower objective clinicians-rated quality of life (HQOL). This
is in contrast to the "depressive realism" found in mild-to-moderatelybjective life satisfaction depended on level of insight impairment.
Fig. 5. Relationships of insight into illness and subjective life satisfaction assessment to dropout and uncooperativeness.
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tal illness andmore accurate self-assessment of current functioning sta-
tus (Alloy and Abramson, 1988; Mohamed et al., 2009; Moore and
Fresco, 2012; Smith et al., 2004). Both groups present important chal-
lenges to healthcare providers, underscoring the need for customized
treatment interventions that cater to their speciﬁc needs, which might
range from focused interventions for depression to adjunctive cognitive
behavioral therapy (CBT) for improving insight, neurocognitive perfor-
mance, functioning (objective QoL), and treatment adherence (Lincoln
et al., 2007; Turner et al., 2014).
In the above-mentioned longitudinal analysis of CATIE data
(Mohamed et al., 2009), improved insight was associated with reduc-
tion in symptoms as assessed by PANSS total and subscales, and im-
provement in objective functioning as assessed by HQOL total and 4
subscales. These longitudinal results are consistent with ﬁndings in
this cross-sectional analysis as well as the meta-analysis by Lincoln
et al. (2007), which together lend support to the observation that im-
proved insight is associated with greater likelihood for improved func-
tioning and long-term outcomes. Reducing insight impairment in
conjunction with neurocognitive and functional deﬁcits may improve
long-term outcomes, including both objective and subjective quality of
life in patients with schizophrenia.
A limitation of this study involves the use of cross-sectional data to
examine the association of subjective QoL with objective functioning,
insight and neurocognitive function, which may not be consistent
with their causal relationships. The use of a one-item scale for measur-
ing sQoL can be another limitation. The psychometric relationship of
this measure of sQoL to various dimensions of life satisfaction in the
full LehmanQoL Interview scale (LQOLI) and other subjective QoL scales
(e.g. the Lancashire scale or the Satisfaction with Life Scale) (Diener
et al., 1985; Lehman, 1988; van Nieuwenhuizen et al., 2001) remains
unknown. In addition, the links between sQoL and the Heinrichs HQOL
scale may have been inﬂated in this study, since the Heinrich's scale
was developed to assess both the deﬁcit syndrome as well as objective
functioning, and the deﬁcit syndrome includes aspects of poor sQoL as
part of its deﬁnition. There is, however, a consistent relationship be-
tween the levels of depressive symptoms and sQoL, thus supporting
the external validity of sQoL (Insel, 2010).
To conclude, our ﬁndings highlight the complex nature of using sub-
jective QoL measures to assess patient recovery and effectiveness of
treatment in chronic schizophrenia, and the importance of reducingcognitive and insight impairments for improving both treatment com-
pliance and long-term functional outcomes.
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